Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455146 | 0.90 | KMT2A (0.50) | KMT2ACTBP2L3MBTL1NPC1RAB9A | |
| SCHEMBL4659000 | 0.84 | CA2 (0.52) | KMT2ACTBP2LMNAL3MBTL1NPC1 | |
| SCHEMBL4641827 | 0.82 | POLB (0.54) | KMT2ACTBP2L3MBTL1NPC1RAB9A | |
| SCHEMBL27511512 | 0.82 | LOXL2 (0.47) | KMT2ACYP4F2CYP4A11 | |
| SCHEMBL4642293 | 0.82 | KMT2A (0.49) | KMT2ACTBP2LMNATDP1MEN1 | |
| SCHEMBL28629859 | 0.82 | KMT2A (0.61) | KMT2ACTBP2LMNAL3MBTL1NPC1 | |
| SCHEMBL7896900 | 0.82 | CYP4F2 (0.42) | KMT2ALMNAL3MBTL1TDP1CYP4F2 | |
| SCHEMBL248114 | 0.82 | TSHR (0.58) | KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL287998 | 0.81 | CYP4F2 (0.50) | KMT2ALMNAL3MBTL1TDP1MAPT | |
| SCHEMBL3231401 | 0.81 | KMT2A (0.58) | KMT2ACTBP2L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458742-B1 | SOLVATES OF 3.BETA.,28-DIACETOXY-18-OXO-19,20,21,29,30-PENTANORLUPAN-22-OIC ACID, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CYCLACEL LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| US-7312356-B2 | Medicament | CYCLACEL LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-20050159484-A1 | Medicament | CYCLACEL LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
| EP-1458742-A2 | SOLVATES OF 3.BETA.,28-DIACETOXY-18-OXO-19,20,21,29,30-PENTANORLUPAN-22-OIC ACID, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | Cyclacel Limited (GB) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003045971-A2 | SOLVATES OF 3.BETA., 28-DIACETOXY-18-OXO-19, 20, 21, 29, 30-PENTANORLUPAN-22-OIC ACID, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CYCLACEL LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
| US-4167407-A | 1-Thiadiazolyl-5-acylimidazolidinones | VELSICOL CHEMICAL CORPORATION (US) | 1979-09-11 | — | — | US | disclosed |
| US-4018787-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1977-04-19 | — | — | US | disclosed |
| US-4006009-A | 1-Thiadiazolyl-6-acyloxytetrahydropyrimidinone herbicides | VELSICOL CHEMICAL CORPORATION (US) | 1977-02-01 | — | — | US | disclosed |
| US-4004912-A | 1-Thiadiazolyl-6-acyloxytetrahydropyrimidinone herbicides | VELSICOL CHEMICAL CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159484-A1 | Medicament | CYP27A1, CYP11B2, CYP46A1 | KMT2A 4373/4885CTBP2 4472/4885LMNA 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.